ArticleNature2019
Tumour lineage shapes BRCA-mediated phenotypes.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 259 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 1 pooled it
45.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
259 citing papers in PubMed, 1 synthesis or guideline pooled it, 402 citations in OpenAlex.
- Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.European urology · 2025Pooled it
- Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.JCO precision oncology · 2026Trial
- A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors.The Journal of clinical endocrinology and metabolism · 2025Trial
- A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma.European urology oncology · 2025Trial
- Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.Journal for immunotherapy of cancer · 2025Trial
- The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).Journal of ovarian research · 2024Trial
- Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).BMC cancer · 2021Trial
- Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).British journal of cancer · 2026Article
- Bridging the gap: integrating hereditary cancer into precision oncology.European journal of human genetics : EJHG · 2026Review
- Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type.Gynecologic oncology reports · 2026Article
- Why are Some Tissues More Vulnerable? Revisiting Tissue Specificity in Hereditary Cancer Syndromes.Molecular diagnosis & therapy · 2026Review
- Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies.BMC cancer · 2026Article
- Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.Cancer cell · 2026Article
- Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant.American journal of medical genetics. Part A · 2026Article
- Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy.Cancer science · 2026Article
- Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.Breast cancer research : BCR · 2026Review
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma.JCO precision oncology · 2026Article
- Cancer genomic profiling predicts pathogenicity ofmedRxiv : the preprint server for health sciences · 2026Article
199 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
31 authors at 4 institutions in 1 country.
Philip JonssonMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chaitanya BandlamudiMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael L ChengDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Preethi SrinivasanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shweta S ChavanMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noah D FriedmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ezra Y RosenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Allison L RichardsMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nancy BouvierMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S Duygu SelcukluMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Craig M BielskiMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diana MandelkerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ozge BirsoyDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Liying ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark T A DonoghueMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
José BaselgaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth OffitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Howard I ScherDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikolaus SchultzMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas D SocciMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Agnes VialeMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc LadanyiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark E RobsonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. bergerm1@mskcc.org.
David B SolitMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. solitd@mskcc.org.
Barry S TaylorMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylorb@mskcc.org.
Memorial Sloan Kettering Cancer Center · USMolecular Oncology (United States) · USAstraZeneca (United States) · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OSTROVNAYA, IRINA · 2018 to 2024
$11.8MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9M(PQ3) Integrative biomarkers of cancer progression and therapeutic response from germline and somatic clinical sequencingR01CA227534 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERGER, MICHAEL F. · 2019 to 2023
$3.5MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MTargeting AKT-Mutant Human CancersR01CA207244 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2016 to 2020
$2.0MMSK Computational Biology Summer ProgramR25CA233208 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael F. Berger, Yaihara Myriam Fortis-Santiago · 2019 to 2026
$1.8MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA221745NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA207244NCI NIH HHS R01 CA227534NCI NIH HHS R25 CA233208NIH HHS U54 OD020355
Abstract
Mutations in BRCA1 and BRCA2 predispose individuals to certain cancers
Indexed as
Cell LineageGenes, BRCA1Genes, BRCA2MutationPhenotypeAllelesCohort StudiesHeterozygoteHumansNeoplasmsPoly(ADP-ribose) Polymerase InhibitorsZygotePoly(ADP-ribose) Polymerase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.